Skip to main content

Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · IEX Real-Time Price · USD
-0.20 (-1.60%)
After-hours:Oct 20, 2021 5:39 PM EDT
1.02 (8.88%)
At close: Oct 20, 4:00 PM
Market Cap409.50M
Revenue (ttm)n/a
Net Income (ttm)-52.74M
Shares Out32.73M
EPS (ttm)-1.61
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close11.49
Day's Range11.23 - 12.57
52-Week Range10.89 - 19.00
Price Targetn/a
Est. Earnings Daten/a

About PYXS

Pyxis Oncology is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We have developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discov...

IPO DateOct 8, 2021
CEOLara Sullivan, M.D.
Stock ExchangeNASDAQ
Ticker SymbolPYXS
Full Company Profile

Financial Performance

Financial Statements


Pyxis Announces Pricing of Upsized Initial Public Offering

Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal...

1 week ago - GlobeNewswire

Pyxis Oncology IPO Registration Document (S-1)

Pyxis Oncology, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC